Navigation Links
Cambridge Laboratories Announces Approval of Tetrabenazine in Spain
Date:12/8/2008

DUBLIN and NEWCASTLE, England, December 8 /PRNewswire/ --

- Marketing Partner UCB Expects to Receive Completed Price and Reimbursement Approval for Tetrabenazine in H1 2009

- Exclusive Distribution Rights Granted in Finland (MediFront) and Taiwan (Giddi Pharma); Distribution Contracts Renewed in Australia and New Zealand

Cambridge Laboratories Limited ("Cambridge" or "the Company"), the privately-owned specialty pharmaceutical company, today announces that its flagship product Tetrabenazine, (known as NITOMAN(R) in Germany and other key European territories and XENAZINE(R) in the UK, US and other markets) has received marketing approval in Spain from the Agencia Espanola de Medicamentos y Productos Sanitarios.

The Company also announces that it has recently signed distribution agreements for Tetrabenazine in Finland and Taiwan, and renewed existing arrangements in Australia and New Zealand.

Tetrabenazine will be marketed as NITOMAN(R) in Spain by Cambridge's marketing partner UCB upon successful completion of all related procedures. It has been approved for the treatment of movement disorders associated with Huntington's disease, a condition for which there is major unmet medical need.

Cambridge has recently renegotiated its agreements with UCB in Spain and Portugal, giving UCB ten year exclusive marketing rights to Tetrabenazine in Spain. UCB, a global biopharmaceutical company, is focused on severe diseases in three therapeutic areas - inflammation, oncology and neurology. The renegotiated terms follow UCB's acquisition of Celltech, Cambridge's former partner in Spain and Portugal, and the more recent merger of UCB with Schwarz Pharma.

UCB is currently in the process of applying for price and reimbursement in Spain and expects to have this procedure completed in the first half of 2009.

Mark Evans, CEO of Cambridge, said: "The granting of a
'/>"/>

SOURCE Cambridge Laboratories Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters
2. IBT Laboratories Expands its Menu of Tests for Immune Deficiency
3. Roxane Laboratories, Inc. Updated Launch of Calcium Acetate Capsules, 667mg
4. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
7. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
8. Northfield Laboratories Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers
9. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
10. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
11. Romark Laboratories Raises $18 Million in Institutional Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , RARITAN, N.J., Dec. 4 ...ttention Deficit Hyperactivity Disorder (ADHD), sl...orbidities reported to occur more often in people ...sus those without an epilepsy diagnosis, according...cross the U.S. ,, Findings from " CNS-Related C...
(Date:12/3/2009)..., , MADISON, N.J., Dec. 3 /PRNewswire-Fir... patient,s risk of developing a potentially life-t...armaceutical therapies or chemicals is one of seve...ostics leader Quest Diagnostics (NYSE: DGX ) wil...tology (ASH) Annual Meeting and Exposition, Decemb...
(Date:12/3/2009)..., , WARRENDALE, Pa., Dec. 3 /PRN...demonstrated PACS* injection-record integration ca...of North America in Chicago. The Connect.PACS(TM...cs capabilities of its kind, is the latest release...rmatics Platform . ,, (Photo: http://www.ne...
Breaking Medicine Technology:Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 2MEDRAD Demonstrates PACS Injection-Record Integration at RSNA 2009 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 1Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 2Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 3Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 4Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 5Orexigen 28R 29 Therapeutics Phase 2b Trial for Empatic 28TM 29 Meets Primary Efficacy Endpoint Demonstrating Significantly Greater Weight Loss Versus 58518 6Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 1Edifecs 28TM 29 Provides Free Commercial Off The Shelf 28COTS 29 Solution for Medicare Administrative Contractors 28MACs 29 58515 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 1Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 2Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 58512 3
(Date:12/4/2009)...ec. 4 Care Investment T...) today announced that its Board of Directors has ...tock. The dividend is payable on December 22, 200... 2009. ,, About Care Investment Trust ,...stment and finance company investing in healthcare...
(Date:12/4/2009)...ISCO, Dec. 4 Medithrive, Inc. has ...pensary in the SF Bay Area by popular vote conduct...ite only three months in operation, the SF Bay com...ocation for accessing medicinal marijuana. ,,...rms the obvious: a dispensary which caters to the ...
(Date:12/4/2009)... Dec. 4 The American As...SA) applauds the Senate for ensuring that the Com...isions remain in the final health reform legislati...ing support to elders, people with disabilities an...ass a health care reform bill that will make it af...
(Date:12/4/2009)...TY, Mo., Dec. 4 The large, two-day...ciation of Free Clinics (NAFC) in Kansas City on W... also for anyone who is uninsured and has not seen... clinic will receive preventive primary care. ,...rge free clinic events this fall in Houston, New O...
(Date:12/4/2009)... Calif., Dec. 4 Pamela Bowen, Chie...selected as a finalist for the "Chief Innovation O...iness with the power of cloud computing. Appy Awar...ve usage of Salesforce CRM or the Force.com platfo...heir sales, marketing, partner, service, support o...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
...oung people appear to be developing the most commo...a dramatic increase in the cost and suffering //ca... overexposure to ultraviolet light from the sun, u...almost always curable and that together afflict 1 ...
... years since the Transplantation of Human Organ Ac...ay with the programme. This has been due to variou...irection and the will to seriously consider this a...idney scandal there is a knee jerk reaction from v...
...ug Digoxin or Digitalis, which comes from the foxg...t efficiently by maintaining the rhythm of the hea...f the drug is changed by the team of researchers f... which works by changing the sugars attached to th...
...s have shown that the efficacy of low-carb diets c... researchers question whether raising protein inta...cent study researchers set out to test the hypothe...ight loss. However some are of the opinion that pr...
...se are crucial factors. But according to the resea...reventive Medicine, // it has been found that calo...ath by heart disease. The finding was based on... done from 1971 to 1975. The participants were gro...
...ould not be a factor in determining transplant el...hown that older heart transplant patients do just ...archers evaluated all 275 adult patients who recei...o 11 years following surgery. Results showed no st...
Other Medicine News:Health News:The Potential Of Cadaver Transplantation Programme In India 2Health News:The Potential Of Cadaver Transplantation Programme In India 3Health News:Finding The Key To Weight Loss! 2
Plasmacup SC
Trabecular Metal Modular Acetabular System
BiHAPro Acetabular Cup
Gap II Revision Cup
Medicine Products: